Litterst C L, Magin R
Laboratory of Biochemical Pharmacology, National Cancer Institute, Bethesda, MD 20892.
Cancer Chemother Pharmacol. 1988;22(1):1-4. doi: 10.1007/BF00254171.
Rats were inoculated s.c. with the Walker 256 solid carcinosarcoma, and when tumors reached a weight of approximately 2-3 g, pharmacokinetics, tissue distribution, and urinary excretion of 195mPt-labelled cisplatin were studied. Cisplatin was given i.v., blood was sampled through arterial cannulae, and data were fitted to a three-compartment model. Distribution half-times were prolonged two- to threefold in tumor-bearing animals, although there was no change in elimination half-time. Initial and steady-state volumes of distribution were also increased in tumor-bearing animals. There was no change in AUC, urinary excretion, tissue distribution, or plasma protein binding. The results indicate that a solid tumor represents an additional compartment for distribution of cisplatin and alters the rate at which cisplatin is distributed from the plasma.
将Walker 256实体癌肉瘤皮下接种到大鼠体内,当肿瘤重量达到约2 - 3克时,研究了195mPt标记的顺铂的药代动力学、组织分布和尿排泄情况。顺铂通过静脉注射给药,通过动脉插管采集血液样本,并将数据拟合到三室模型。荷瘤动物的分布半衰期延长了两到三倍,尽管消除半衰期没有变化。荷瘤动物的初始分布容积和稳态分布容积也增加了。曲线下面积、尿排泄、组织分布或血浆蛋白结合均无变化。结果表明,实体瘤是顺铂分布的另一个隔室,并改变了顺铂从血浆中分布的速率。